Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.
The Journal of Parkinson's Disease and its publisher IOS Press are proud to announce the two articles that have won the first Parkinson Prize, recognizing these outstanding contributions to the advancement to Parkinson's disease research.
Two newer types of medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
Phillip Robinson has gone from 10 cigarettes a day to one or two every other day after enrolling in a smoking cessation clinical trial launched by researchers at The University of Texas Health Science Center at Houston
Almost two-thirds of non-diabetic patients with Parkinson's disease may be insulin resistant, despite having normal blood sugar, report scientists in the Journal of Parkinson's Disease.
Non-motor symptoms of Parkinson's disease, such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits.
A new study by UCL, University of Oxford and Queen Mary University of London researchers suggests that people with type 2 diabetes are 32% more likely to develop Parkinson’s disease than those without diabetes.
Making tiny changes to existing diabetes treatments can alter how they interact with cells, and potentially make the medicines more effective.
Chemist Robert Doyle in the College of Arts and Sciences at Syracuse University has figured out how to control glucose levels in the bloodstream without the usual side effects of nausea, vomiting or malaise.
Diabetes patients who take the most commonly prescribed diabetes drug, metformin, are the least likely to follow medical advice regarding their medication due its side effects, a new article in the journal Diabetes, Obesity and Metabolism reports.
Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's.
Research shows that using a glucagon-like peptide-1 receptor agonist instead of a rapid-acting insulin analogue at mealtimes can reduce glycaemic variability in high-risk patients with Type 2 diabetes.
A medication approved to treat various respiratory diseases and that has demonstrated neuroprotective effects in preclinical studies is the focus of a new clinical trial for Parkinson's disease.
Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) differ in their efficacy and safety profiles, according to new research by the University of Leicester.
What doesn't kill you could cure you. A growing interest in the therapeutic value of animal venom has led a pair of Columbia University data scientists to create the first catalog of known animal toxins and their physiological effects on humans.
An intestinal patch device containing insulin that can be swallowed in the form of a capsule, in development by researchers at University of California Santa Barbara, has demonstrated efficacy of blood glucose management in diabetic rats. This work is being presented Oct. 27 at the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Orlando, Fla. Oct. 25-29.
AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).
Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.
Gut hormone-based medications used to treat diabetes, such as GLP-1 receptor agonists, have also been shown to reduce body weight. Researchers have been working to understand how. This study, presented today at the American Diabetes Association's 75th Scientific Sessions, sheds light on how GLP-1 receptor agonists alter the brain's response to food, possibly reducing cravings and increasing satisfaction while eating.
Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association.
Intarcia Therapeutics, Inc. today announced the closing of a $225 million synthetic royalty financing with an equity conversion option at a $5.5 billion Company valuation. Plans are to use these funds to accelerate the initiation of additional head-to-head comparative and switch studies of ITCA 650 vs. leading oral and injectable type 2 diabetes therapies.